Phathom Pharmaceuticals, Inc. focuses on developing and commercializing treatments for gastrointestinal diseases.The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
